Literature DB >> 17266385

The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003.

Frank R Lichtenberg1.   

Abstract

OBJECTIVE: To test the hypothesis that, ceteris paribus, people using newer, or later vintage drugs will be in better health, and will therefore be less likely to be admitted to hospitals and nursing homes, by examining the effect of pharmaceutical innovation on the utilisation of hospital and long-term care by elderly Americans during 1997-2003.
DESIGN: An estimation of difference-in-differences models of hospital discharge rates using longitudinal state-level data on 12 states. Data on the utilisation of over 43 000 products, by state and year, were obtained from state Medicaid agencies. The extent of utilisation of new drugs in the Medicaid programme is strongly correlated with the extent of utilisation of new drugs in general. PATIENTS OR STUDY PARTICIPANTS: All elderly residents of 12 states during the period 1997-2003. INTERVENTION: The relative utilisation of new and old drugs. MAIN OUTCOME MEASURES: Discharges per elderly individual, discharges to nursing homes per elderly individual, and inpatient deaths per elderly individual.
RESULTS: States that had larger increases in drug vintage had smaller increases in the number of hospital discharges per elderly individual. They also had smaller increases in the number of hospital discharges to nursing homes and the number of in-hospital deaths per elderly individual.
CONCLUSIONS: Even the upper-bound estimate of the increase in 2003 drug expenditure attributable to the 1997-2003 increase in drug vintage is lower than the sum of the lowest estimates of the 2003 hospital and nursing home expenditure reductions attributable to the 1997-2003 increase in drug vintage.

Entities:  

Mesh:

Year:  2006        PMID: 17266385     DOI: 10.2165/00019053-200624003-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

1.  Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Authors:  B Motheral; K A Fairman
Journal:  Med Care       Date:  2001-12       Impact factor: 2.983

2.  Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.

Authors:  F R Lichtenberg
Journal:  Health Aff (Millwood)       Date:  2001 Sep-Oct       Impact factor: 6.301

3.  Do (more and better) drugs keep people out of hospitals?

Authors:  F R Lichtenberg
Journal:  Am Econ Rev       Date:  1996-05

4.  The National Nursing Home Survey: 1999 summary.

Authors:  Adrienne Jones
Journal:  Vital Health Stat 13       Date:  2002-06

Review 5.  The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.

Authors:  Frank R Lichtenberg
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

  5 in total
  5 in total

1.  Bias in high-tier medical journals concerning physician-academic relationships with industry.

Authors:  Roman Lesko; Samuel Scott; Thomas P Stossel
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

2.  Medicaid preferred drug lists: cost containment and side effects.

Authors:  Alvin E Headen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Impact of new drugs and biologics on colorectal cancer treatment and costs.

Authors:  Pinar Karaca-Mandic; Jeffrey S McCullough; Mustaqeem A Siddiqui; Holly Van Houten; Nilay D Shah
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  The quality of medical care, behavioral risk factors, and longevity growth.

Authors:  Frank R Lichtenberg
Journal:  Int J Health Care Finance Econ       Date:  2010-12-25

5.  Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants.

Authors:  Travis C Porco; Bryan Lewis; Elliot Marseille; Jennifer Grinsdale; Jennifer M Flood; Sarah E Royce
Journal:  BMC Public Health       Date:  2006-06-19       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.